Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Novo Nordisk stock faces bearish technicals, but analysts forecast nearly 46% upside. Novo inks $285 million Ascendis deal, ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...

Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss medicine ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has successfully concluded a share repurchase program initiated on August 7, 2024, ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Wells Fargo analyst Derek Archila maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of ...

Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in ...